Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.
- Published In:
- International journal of chronic obstructive pulmonary disease, 13, 3191-3202 (2018)
- Authors:
- Huang, Jingwen, Yi, Huahua, Zhao, Chunliu, Zhang, Yifan, Zhu, Liying, Liu, Bing, He, Ping, Zhou, Min
- Database ID:
- RPEP-03717
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03717APA
Huang, Jingwen; Yi, Huahua; Zhao, Chunliu; Zhang, Yifan; Zhu, Liying; Liu, Bing; He, Ping; Zhou, Min. (2018). Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.. International journal of chronic obstructive pulmonary disease, 13, 3191-3202. https://doi.org/10.2147/COPD.S175145
MLA
Huang, Jingwen, et al. "Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.." International journal of chronic obstructive pulmonary disease, 2018. https://doi.org/10.2147/COPD.S175145
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliora..." RPEP-03717. Retrieved from https://rethinkpeptides.com/research/huang-2018-glucagonlike-peptide1-receptor-glp1r
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.